Arcutis Biotherapeutics, Inc.

What they do

Arcutis develops and commercializes topical treatments for immune-mediated dermatological diseases, centered on roflumilast, a once-daily phosphodiesterase-4 (PDE4) inhibitor. The company markets ZORYVE cream 0.3%, cream 0.15%, cream 0.05%, and ZORYVE foam 0.3% across three indications: plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. It sells in the U.S. and Canada, and in July 2024 signed a promotion agreement with Kowa Pharmaceuticals America to use Kowa's primary care sales force to market and promote ZORYVE in the United States. It also has an earlier-stage pipeline, including ARQ-234, a CD200 receptor checkpoint agonist fusion protein, and Phase 2 studies of ZORYVE foam in vitiligo and hidradenitis suppurativa.

Revenue drivers

• ZORYVE net product sales (total franchise) — Essentially all revenue comes from ZORYVE net product sales, which reached $129.9 million in Q2 2026, up 59% year over year and 23% sequentially.
• Plaque psoriasis — ZORYVE cream 0.3% was the first approval (August 2022 launch) and has been expanded down to age 2 in June 2026; the foam was approved for scalp and body plaque psoriasis in adults and adolescents 12+ in May 2025 and launched in the U.S. in June 2025.
• Seborrheic dermatitis — ZORYVE foam 0.3% was approved in December 2023 as the first drug for seborrheic dermatitis with a new mechanism of action in over two decades, and launched in the U.S. in January 2024 and Canada in November/December 2024.
• Atopic dermatitis — ZORYVE cream 0.15% launched July 2024 for adults and children 6+, and cream 0.05% launched October 2025 for children 2 to 5; an sNDA for infants 3 to 24 months has a PDUFA date of February 23, 2027.

Recent performance

Q2 2026 revenue was $129.9 million, up 59% versus Q2 2025 and 23% versus Q1 2026, driven by demand growth and improved gross-to-net pricing. Full-year 2025 revenue was $376.1 million with a net loss of $16.1 million, compared with $196.5 million of revenue and a $140.0 million net loss in 2024. Operating cash flow improved from negative $112.2 million in 2024 to negative $5.6 million in 2025, and the company reported positive operating cash flow for Q2 2026. As of June 30, 2026, Arcutis reported $488.5 million in total assets, $268.0 million in total liabilities, $220.6 million in shareholder equity, $34.1 million in cash and equivalents, and $102.0 million of long-term debt. The company also completed hiring of a targeted sales team for primary care and pediatric providers, with field launch anticipated by the end of August 2026.

Strategy

Arcutis' stated strategy is to focus on validated biological targets and use its dermatology development and commercialization platform to build differentiated products. It is expanding the ZORYVE label through supplemental filings, including the June 2026 approval of cream 0.3% for children down to age 2 and the pending infant atopic dermatitis sNDA with a February 23, 2027 PDUFA date. It is investing in commercial reach by building a primary care and pediatric sales team, launching a virtual health platform, and partnering with an AI-enabled healthcare platform to streamline access. Pipeline priorities include Phase 2 proof-of-concept studies of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and a Phase 1a/1b first-in-human study of ARQ-234.

Risks

• Concentration in a single franchise — Revenue depends almost entirely on ZORYVE across its cream and foam formulations, so any competitive, pricing, or reimbursement setback for the franchise would directly hit total sales.
• History of losses — Arcutis has incurred losses each year since inception in June 2016, with a 2025 net loss of $16.1 million and an accumulated deficit of $1,138.1 million as of December 31, 2025.
• Going-concern and funding needs — The 10-K forward-looking statements reference the company's ability to continue as a going concern and obtain funding, including satisfying conditions, covenants, and obligations under its amended loan and security agreement with SLR Investment Corp.
• Regulatory and label-expansion risk — Growth plans rely on FDA and Health Canada approvals of supplemental applications, such as the infant atopic dermatitis sNDA with a February 23, 2027 target action date, which may not be granted or may be delayed.

Outlook

Management raised 2026 full-year net product sales guidance to $525 million to $540 million. It expects to report topline results and a program advancement decision for the Phase 2 vitiligo study of ZORYVE foam 0.3% in Q4 2026, and a decision for the hidradenitis suppurativa Phase 2 program in Q1 2027. The FDA has set a February 23, 2027 PDUFA target date for ZORYVE cream 0.05% in infants aged 3 to 24 months with atopic dermatitis.